LDS Technology Overview

At LDS, we’ve pioneered an exclusive, innovative platform delivery technology capable of handling a diverse range of active molecules, including those with poor solubility and permeability (Class III and IV as per the BCS classification). Our technology finds applications across various industries, including pharmaceuticals, nutraceuticals, and cosmeceuticals, offering versatile delivery methods such as creams, tablets, sprays, gels, viscous, or non-viscous solutions to suit different needs. Comprising lipid-based, safe, and non-toxic ingredients infused with specialized “membrane recognition” and “permeation agents,” our flexible structures serve as carriers for both small and large active molecules, ensuring enhanced bioavailability. Our technology stands out for its cost-effectiveness, ease of production, and stability in a wide range of temperatures and conditions. By providing an innovative alternative to traditional delivery methods, we aim to revolutionize the field of drug delivery and contribute to better health outcomes.

We use the most sophisticated and advanced equipment

We have access to state-of-the-art analytical tools in our own laboratories or in the Nano-Center at the Hebrew University, which allows us to characterize and to understand the nano-domain structures and properties profoundly, both in the development stages and after production.

Unique structure that enhances delivery

The core technology at LDS is derived from new molecular engineering models that allow the formation of new types of modified nano-domains. The domains are “coronated” in their interface with membrane recognition molecules and permeation agents facilitating the active molecule’s efficient transport.
The structures enable intimate contact with the target tissue surfaces, facilitating the diffusion of the active molecule across the membrane. Furthermore, the structures include components that allow the delivery of the active molecule to the surfaces or the membrane’s interface without any intermediary.

Controlled release at the required rate

LDS carefully selects the proper ingredients to allow each nano-domain to solubilize a specific active molecule at a required loading capacity. The nature of the active molecule and its embedding on the interface of the nano-domains (and not in their core) can be manipulated to achieve controlled release.
We customize the active molecule release using few proprietary nano-structures that work together to optimize the active molecule solubility and deliverability and the order of the structure.

Chaotropic guest molecules
disordering the structure

Cosmotropic guest molecules increasing the order

How does it work?

The tailor-made ‘oily’ nano-domains are designed and prepared by loading the active molecules at the interface or core of the structures. The domains are coronated with several excipients facilitating the permeation of the active molecules across surfaces, or membranes (‘permeating agents’). Only once the nano-domains migrate to the interface and recognize the delivery site will the structure adhere to the surface and allow the active molecule to be released by diffusion.
The delivery is processed in four main steps:

Migration of the nano-domains to the membrane

The nano-domains recognize the specific membrane surface onto which they will adhere.

The nano-domains adhere to the membrane

The nano-domains adheres to the membrane and the active molecule is released by membrane undulation.

Active molecules permeate the membrane

The nano-domains’ intimate contact with the membrane allows passive diffusion of the active molecules.

The nano-domains depart from the membrane

The empty vehicles depart from the adsorbing site and are discharged from the body.

Publications

Tehila Mishraki-Berkowitz Guy Cohen Abraham Aserin, N. Garti. Colloids Surfaces B, Biointerfaces 2018, 12;161: 670-676.

R.E. Hoffman, E. Darmon, A. Aserin, N. Garti, Part 1- Proof of concept. Journal of Colloid and Interface Science, 2016, 463, 349-357.

T. Mishraki-Berkowitz, P. Ben Ishai, A. Aserin, Yu. Feldman, N. Garti. Physical Chemistry Chemical Physics,2015, 17(14), 9499-9508.

M. Cohen-Avrahami, A. I. Shames2, M. F. Ottaviani3, A. Aserin, N. Garti, Colloids and Surfaces B. Biointerfaces, 2014, 122, 231-240.

V.L. Kolev, A.N. Ivanova, G.K. Madjarova, A. Aserin, N. Garti, Journal of Physical Chemistry B, 2014, 118(20), 5459-5470.

L. Bitan-Cherbakovsky, A. Aserin, N. Garti, Colloids and Surfaces, B: Biointerfaces ,2013, 112, 87-95.

T. Mishraki, P. Ben Ishai, D. Babukh, A. Aserin, Y. Feldman, N. Garti, Journal of Colloid and Interface Science; 396, 2013178-186.

M. Cohen-Avrahami, D. Libster, A. Aserin, N. Garti, Journal of Controlled Release,2012, 159(3), 419–428.

I. Amar-Yuli, J. Adamcik, S. Blau, A. Aserin, N. Garti, R. Mezzenga, Soft Matter ,2011, 7(18), 8162-8168.

J. Gurfinkel, A. Aserin, N. Garti, Colloids and Surfaces A: Physicochemical and Engineering Aspects ,2011, 392(1), 322-328. D. Libster, A. Aserin, N. Garti. Interactions of biomacromolecules with reverse hexagonal liquid crystals: Drug delivery and crystallization applications. Journal of Colloid and Interface Science ,2011, 356(2), 375-386.4.

L. Bitan-Cherbakovsky, D. Libster, A. Aserin, N. Garti, Journal of Physical Chemistry B, 2011, 115(42), 11984-11992.

R. Efrat, Z. Abramov, A. Aserin, N. Garti, Journal of Physical Chemistry B ,2010, 114(33), 10709-10716.

L. Bitan-Cherbakovsky, I. Yuli-Amar, A. Aserin, N. Garti, Langmuir,2010, 26(5), 3648-3653.

T. Mishraki, D. Libster, A. Aserin, N. Garti, Colloids Surf. B 2010, 75(2), 391-397.

Patents

Enclosed is a list of the approved and the filed patents of LDS new delivery technology. The patents list is providing a quick glance and an introduction of LDS patents family.

Hexagonal systems for use in solubilizing, protecting and delivery of bio-macromolecule and/or active compounds.
Patents granted.

Mediums and methods for selective extraction of active compounds from plant material (including selective cannabinoids extraction).
Pending patent applications.
 

Solubilization in high loads of cannabinoids for fast and efficient delivery for oral applications
Pending patent applications.

Various novel nano-domains formulations for various administration routes of active compounds, including injectables, oral, topical formulations, etc.
Pending patent applications and granted patents.